Skip to main content
PMC home page
Medline Book to support NIHPA logoLink to Medline Book to support NIHPA
. 2020 Jan;24(2):1–180. doi: 10.3310/hta24020

Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.

Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Juliet Hounsome, Rui Duarte, Aditya Shenoy
PMCID: PMC6983913  PMID: 31931920

Abstract

BACKGROUND

Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies in England and Wales. Differentiated thyroid cancer (DTC) accounts for ≈94% of all thyroid cancers. Patients with DTC often require treatment with radioactive iodine. Treatment for DTC that is refractory to radioactive iodine [radioactive iodine-refractory DTC (RR-DTC)] is often limited to best supportive care (BSC).

OBJECTIVES

We aimed to assess the clinical effectiveness and cost-effectiveness of lenvatinib (Lenvima®; Eisai Ltd, Hertfordshire, UK) and sorafenib (Nexar®; Bayer HealthCare, Leverkusen, Germany) for the treatment of patients with RR-DTC.

DATA SOURCES

EMBASE, MEDLINE, PubMed, The Cochrane Library and EconLit were searched (date range 1999 to 10 January 2017; searched on 10 January 2017). The bibliographies of retrieved citations were also examined.

REVIEW METHODS

We searched for randomised controlled trials (RCTs), systematic reviews, prospective observational studies and economic evaluations of lenvatinib or sorafenib. In the absence of relevant economic evaluations, we constructed a de novo economic model to compare the cost-effectiveness of lenvatinib and sorafenib with that of BSC.

RESULTS

Two RCTs were identified: SELECT (Study of [E7080] LEnvatinib in 131I-refractory differentiated Cancer of the Thyroid) and DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer). Lenvatinib and sorafenib were both reported to improve median progression-free survival (PFS) compared with placebo: 18.3 months (lenvatinib) vs. 3.6 months (placebo) and 10.8 months (sorafenib) vs. 5.8 months (placebo). Patient crossover was high (≥ 75%) in both trials, confounding estimates of overall survival (OS). Using OS data adjusted for crossover, trial authors reported a statistically significant improvement in OS for patients treated with lenvatinib compared with those given placebo (SELECT) but not for patients treated with sorafenib compared with those given placebo (DECISION). Both lenvatinib and sorafenib increased the incidence of adverse events (AEs), and dose reductions were required (for > 60% of patients). The results from nine prospective observational studies and 13 systematic reviews of lenvatinib or sorafenib were broadly comparable to those from the RCTs. Health-related quality-of-life (HRQoL) data were collected only in DECISION. We considered the feasibility of comparing lenvatinib with sorafenib via an indirect comparison but concluded that this would not be appropriate because of differences in trial and participant characteristics, risk profiles of the participants in the placebo arms and because the proportional hazard assumption was violated for five of the six survival outcomes available from the trials. In the base-case economic analysis, using list prices only, the cost-effectiveness comparison of lenvatinib versus BSC yields an incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained of £65,872, and the comparison of sorafenib versus BSC yields an ICER of £85,644 per QALY gained. The deterministic sensitivity analyses show that none of the variations lowered the base-case ICERs to < £50,000 per QALY gained.

LIMITATIONS

We consider that it is not possible to compare the clinical effectiveness or cost-effectiveness of lenvatinib and sorafenib.

CONCLUSIONS

Compared with placebo/BSC, treatment with lenvatinib or sorafenib results in an improvement in PFS, objective tumour response rate and possibly OS, but dose modifications were required to treat AEs. Both treatments exhibit estimated ICERs of > £50,000 per QALY gained. Further research should include examination of the effects of lenvatinib, sorafenib and BSC (including HRQoL) for both symptomatic and asymptomatic patients, and the positioning of treatments in the treatment pathway.

STUDY REGISTRATION

This study is registered as PROSPERO CRD42017055516.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

Plain language summary

WHAT WAS THE PROBLEM?

Differentiated thyroid cancer is a common type of thyroid cancer. For many patients, radioactive iodine is an effective treatment; however, for some patients, the treatment stops working or becomes unsafe. Two new drugs, lenvatinib (Lenvima®; Eisai Ltd, Hertfordshire, UK) and sorafenib (Nexar®; Bayer HealthCare, Leverkusen, Germany), may be new treatment options.

WHAT DID WE DO?

We reviewed the clinical evidence of lenvatinib and sorafenib. We also estimated the costs and benefits of treatment.

WHAT DID WE FIND?

Compared with no treatment, treatment with lenvatinib or sorafenib may increase the time that people live with thyroid cancer before their disease gets worse; however, both drugs are expensive and may have unpleasant side effects.

WHAT DOES THIS MEAN?

At their published (undiscounted) prices, lenvatinib or sorafenib may not be considered to provide good value for money to the NHS.

Full text of this article can be found in Bookshelf.

References

  1. Cancer Research UK. Thyroid Cancer Incidence Statistics. London: Cancer Research UK. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidence (accessed 5 May 2017).
  2. Cancer Research UK. About Thyroid Cancer. London: Cancer Research UK. URL: www.cancerresearchuk.org/about-cancer/type/thyroid-cancer/about/the-thyroid-gland (accessed 5 May 2017).
  3. Bomeli SR, LeBeau SO, Ferris RL. Evaluation of a thyroid nodule. Otolaryngol Clin North Am 2010;43:229–38. https://doi.org/10.1016/j.otc.2010.01.002 doi: 10.1016/j.otc.2010.01.002. [DOI] [PMC free article] [PubMed]
  4. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard G, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol 2014;81(Suppl. 1):1–122. https://doi.org/10.1111/cen.12515 doi: 10.1111/cen.12515. [DOI] [PubMed]
  5. Canadian Agency for Drugs and Technologies in Health (CADTH). Pan-Canadian Oncology Drug Review Final Clinical Guidance Report Sorafenib (Nexavar) for Differentiated Thyroid Cancer. Ottawa, ON: CADTH; 2015. URL: www.cadth.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf (accessed 16 May 2017).
  6. Canadian Agency for Drugs and Technologies in Health (CADTH). Pan-Canadian Oncology Drug Review Final Clinical Guidance Report: Lenvatinib (Lenvima) for Differentiated Thyroid Cancer. CADTH; 2016. URL: www.cadth.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf (accessed 16 May 2017).
  7. Bayer HealthCare. Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Company submission to NICE. March 2017. URL: www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers (accessed 30 July 2018).
  8. Eisai Ltd. Lenvatinib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Multiple technology appraisal [ID1059]. Company submission to NICE. 2017. URL: www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers (accessed 30 July 2018).
  9. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017;317:1338–48. https://doi.org/10.1001/jama.2017.2719 doi: 10.1001/jama.2017.2719. [DOI] [PMC free article] [PubMed]
  10. Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 2016;23:313–22. https://doi.org/10.1530/ERC-15-0445 doi: 10.1530/ERC-15-0445. [DOI] [PMC free article] [PubMed]
  11. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:2164–7. https://doi.org/10.1001/jama.295.18.2164 doi: 10.1001/jama.295.18.2164. [DOI] [PubMed]
  12. Yao Y, Chiu CG, Strugnell SS, Gill S, Wiseman SM. Gender differences in thyroid cancer. Expert Rev Endocrinol Metab 2011;6:215–43. https://doi.org/10.1586/eem.11.9 doi: 10.1586/eem.11.9. [DOI] [PubMed]
  13. Cancer Research UK. Thyroid Cancer Mortality Statistics. London: Cancer Research UK. URL: www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/mortality (accessed 5 May 2017).
  14. Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res 2012;2012:618985. https://doi.org/10.1155/2012/618985 doi: 10.1155/2012/618985. [DOI] [PMC free article] [PubMed]
  15. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998;83:2638–48. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 doi: 10.1002/(SICI)1097-0142(19981215)83:12&#x0003c;2638::AID-CNCR31&#x0003e;3.0.CO;2-1. [DOI] [PubMed]
  16. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229–42. https://doi.org/10.1089/thy.2006.16.1229 doi: 10.1089/thy.2006.16.1229. [DOI] [PubMed]
  17. Cancer Research UK. Types of Thyroid Cancer. London: Cancer UK. URL: www.cancerresearchuk.org/about-cancer/type/thyroid-cancer/about/types-of-thyroid-cancer (accessed 5 May 2017).
  18. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501–11. https://doi.org/10.1016/S0140-6736(03)12488-9 doi: 10.1016/S0140-6736(03)12488-9. [DOI] [PubMed]
  19. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002;113:241–60. [PMC free article] [PubMed]
  20. Sajid-Crokett S, Hershman J. Thyroid Nodules and Cancer in the Elderly. Updated 2015 May 19. In De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc.; 2000. URL: www.ncbi.nlm.nih.gov/books/NBK278969/ (accessed 27 June 2017).
  21. Clayman G. Hürthle Cell Thyroid Cancer: a Type of Thyroid Tumor and Thyroid Cancer. URL: www.endocrineweb.com/conditions/thyroid-cancer/hurthle-cell-thyroid-tumor (accessed 19 June 2017).
  22. Verburg FA, Mäder U, Tanase K, Thies ED, Diessl S, Buck AK, et al. Life expectancy is reduced in differentiated thyroid cancer patients ≥ 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab 2013;98:172–80. https://doi.org/10.1210/jc.2012-2458 doi: 10.1210/jc.2012-2458. [DOI] [PubMed]
  23. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl. 7):vii110–9. https://doi.org/10.1093/annonc/mds230 doi: 10.1093/annonc/mds230. [DOI] [PubMed]
  24. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020 doi: 10.1089/thy.2015.0020. [DOI] [PMC free article] [PubMed]
  25. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 1. 31 March 2017. URL: www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (accessed 10 May 2017).
  26. European Medicines Agency. CHMP Extension of Indication Variation Assessment Report: Nexavar. Procedure No. EMEA/H/C/000690/II/0035. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/220738/2014. London: European Medicines Agency; 25 April 2014. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000690/WC500168976.pdf (accessed 10 May 2017).
  27. European Medicines Agency. Assessment Report. Lenvima. International non-proprietary name: lenvatinib. Procedure No. EMEA/H/C/003727/0000. Committee for Medicinal Products for Human Use (CHMP). EMA/250082/2015. London: European Medicines Agency; 26 March 2015. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003727/WC500188676.pdf (accessed 10 May 2017).
  28. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer 2003;97:1186–94. https://doi.org/10.1002/cncr.11176 doi: 10.1002/cncr.11176. [DOI] [PubMed]
  29. Muresan MM, Olivier P, Leclère J, Sirveaux F, Brunaud L, Klein M, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 2008;15:37–49. https://doi.org/10.1677/ERC-07-0229 doi: 10.1677/ERC-07-0229. [DOI] [PubMed]
  30. Vachani C, Hoff K. All About Hürthle Cell Carcinoma (updated by Karen Arnold-Korzeniowski; last modified 16 May 2016). URL: www.oncolink.org/cancers/thyroid/all-about-huerthle-cell-carcinoma (accessed 19 June 2017).
  31. Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab 2017;61:81–9. https://doi.org/10.1590/2359-3997000000245 doi: 10.1590/2359-3997000000245. [DOI] [PMC free article] [PubMed]
  32. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9. https://doi.org/10.1210/jc.2005-2838 doi: 10.1210/jc.2005-2838. [DOI] [PubMed]
  33. Gruber JJ, Colevas AD. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist 2015;20:113–26. https://doi.org/10.1634/theoncologist.2014-0313 doi: 10.1634/theoncologist.2014-0313. [DOI] [PMC free article] [PubMed]
  34. Sacks W, Braunstein GD. Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. Endocr Pract 2014;20:263–75. https://doi.org/10.4158/EP13305.RA doi: 10.4158/EP13305.RA. [DOI] [PubMed]
  35. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598–605. [PubMed]
  36. Brose MS. In search of a real ‘targeted’ therapy for thyroid cancer. Clin Cancer Res 2012;18:1827–9. https://doi.org/10.1158/1078-0432.CCR-12-0153 doi: 10.1158/1078-0432.CCR-12-0153. [DOI] [PubMed]
  37. Newbold KL, Flux G, Wadsley J. Radioiodine for high risk and radioiodine refractory thyroid cancer: current concepts in management. Clin Oncol 2017;29:307–9. https://doi.org/10.1016/j.clon.2016.12.008 doi: 10.1016/j.clon.2016.12.008. [DOI] [PubMed]
  38. Scottish Medicines Consortium. Lenvatinib 4 mg and 10 mg Hard Capsules (Lenvima®) SMC No. (1179/16). 9 September 2016. URL: www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf (accessed 17 November 2016).
  39. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid 2009;19:1393–400. https://doi.org/10.1089/thy.2009.1603 doi: 10.1089/thy.2009.1603. [DOI] [PubMed]
  40. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s–9s. https://doi.org/10.1158/1078-0432.CCR-06-0931 doi: 10.1158/1078-0432.CCR-06-0931. [DOI] [PubMed]
  41. Brown RL, de Souza JA, Cohen EE. Thyroid cancer: burden of illness and management of disease. J Cancer 2011;2:193–9. https://doi.org/10.7150/jca.2.193 doi: 10.7150/jca.2.193. [DOI] [PMC free article] [PubMed]
  42. Covell LL, Ganti AK. Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Target Oncol 2015;10:311–24. https://doi.org/10.1007/s11523-014-0331-z doi: 10.1007/s11523-014-0331-z. [DOI] [PubMed]
  43. Food and Drug Administration. Lenvatinib (Lenvima). Silver Spring, MD: Food and Drug Administration; 2015. URL: https://wayback.archive-it.org/7993/20170111231641/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm (accessed 16 May 2017).
  44. Food and Drug Administration. Sorafenib (Nexavar). Silver Spring, MD: Food and Drug Administration; 2015. URL: https://wayback.archive-it.org/7993/20170111231704/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm (accessed 16 May 2017).
  45. European Medicines Agency. Product information: 23/03/2017 Lenvima-EMEA/H/C/003727-WS/1123. Annex I – Summary of Product Characteristics. London: European Medicines Agency. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003727/WC500188674.pdf (accessed 10 May 2017).
  46. European Medicines Agency. Product information: 02/09/2016 Nexavar-EMEA/H/C/000690-N/38. Annex I – Summary of Product Characteristics. First. London: European Medicines Agency. URL: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf (accessed 10 May 2017).
  47. Joint Formulary Committee. British National Formulary. 73rd ed. London: BMJ Group and Pharmaceutical Press; 2017.
  48. Scottish Medicines Consortium. Sorafenib 200mg Film-coated Tablets (Nexavar®) SMC No. (1055/15). 5 June 2015. URL: www.scottishmedicines.org.uk/files/advice/sorafenib_Nexavar_FINAL_June_2015_for_website.pdf (accessed 10 May 2017).
  49. European Medicines Agency. Nexavar (Sorafenib). London: European Medicines Agency. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000690/human_med_000929.jsp&mid=WC0b01ac058001d124 (accessed 10 May 2017).
  50. European Medicines Agency. Lenvima (Lenvatinib). London: European Medicines Agency. URL: www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003727/human_med_001864.jsp&mid=WC0b01ac058001d124 (accessed 10 May 2017).
  51. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–30. https://doi.org/10.1056/NEJMoa1406470 doi: 10.1056/NEJMoa1406470. [DOI] [PubMed]
  52. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 3 trial. Lancet 2014;384:319–28. https://doi.org/10.1016/S0140-6736(14)60421-9 doi: 10.1016/S0140-6736(14)60421-9. [DOI] [PMC free article] [PubMed]
  53. National Institute for Health and Care Excellence (NICE). Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Final scope [ID1059]. London: NICE; December 2016. URL: www.nice.org.uk/guidance/indevelopment/gid-ta10101 (accessed 20 July 2017).
  54. Fleeman N, Houten R, Chaplin M, Beale S, Boland A, Dundar Y, et al. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer 2019;19:1209. https://doi.org/10.1186/s12885-019-6369-7 doi: 10.1186/s12885-019-6369-7. [DOI] [PMC free article] [PubMed]
  55. Liverpool Reviews and Implementation Group. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine. Draft Protocol. Liverpool: Liverpool Reviews and Implementation Group; November 2016. URL: www.nice.org.uk/guidance/gid-ta10101/documents/final-protocol (accessed 21 May 2017).
  56. Centre for Reviews and Dissemination. Systematic Reviews: CRD’s Guidance for Undertaking Reviews in Healthcare. York: Centre for Reviews and Dissemination; 2008. URL: www.york.ac.uk/crd/SysRev/!SSL!/WebHelp/SysRev3.htm#5_5_QUALITY_ASSESSMENT.htm (accessed 24 January 2017).
  57. Tremblay G, Holbrook T, Milligan G, Pelletier C, Rietscheli P. Matching-adjusted indirect treatment comparison in patients with radioiodine-refractory differentiated thyroid cancer. Comp Eff Res 2016;6:13–21.
  58. Brose MS, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial. Ann Oncol 2014;27(Suppl. 6).
  59. Ahmed M, Barbachano Y, Riddell A, Hickey J, Newbold KL, Viros A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a Phase II study in a UK based population. Eur J Endocrinol 2011;165:315–22. https://doi.org/10.1530/EJE-11-0129 doi: 10.1530/EJE-11-0129. [DOI] [PubMed]
  60. Ahmed M, Barbachano Y, Riddell AM, Whittaker S, Newbold K, Harrington K, et al. An open labelled Phase 2 study evaluating the safety and efficacy of sorafenib in metastatic advanced thyroid cancer. Ann Oncol 2008;19:viii–218. https://doi.org/10.1200/jco.2008.26.15_suppl.6060 doi: 10.1200/jco.2008.26.15_suppl.6060. [DOI]
  61. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid 2013;23:392–407. https://doi.org/10.1089/thy.2012.0520 doi: 10.1089/thy.2012.0520. [DOI] [PubMed]
  62. Ball D, Sherman S, Jarzab B, Cabanillas M, Licitra L, Pacini F, et al. A Phase II trial of the multi-targeted kinase inhibitor lenvatinib (E7080) in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC): Correlation of treatment outcomes with tumor genetic analysis, serum biomarkers and pharmacokinetics. Thyroid 2011;21:A6–7.
  63. Ball DW, Sherman SI, Jarzab B, Cabanillas ME, Martins R, Shah MH, et al. Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response. J Clin Oncol 2012;30(15 Suppl. 1).
  64. Bastholt L, Brose MS, Jarzab B, Schlumberger M, Siena S, De La Fouchardiere C, et al. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the Phase III DECISION trial. J Clin Oncol 2014;32(Suppl. 1).
  65. Bockisch A, Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The Phase III DECISION trial. Exp Clin Endocrinol Diabetes 2014;122. https://doi.org/10.1055/s-0034-1372011 doi: 10.1055/s-0034-1372011. [DOI]
  66. Brose M, Jarzab B, Elisei R, Giannetta L, Bastholt L, De La Fouchardiere C, et al. Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the Phase 3 DECISION trial: an exploratory crossover adjustment analyses. Ann Oncol 2016;27. https://doi.org/10.1093/annonc/mdw376.06 doi: 10.1093/annonc/mdw376.06. [DOI]
  67. Brose M, Schlumberger M, Tahara M, Wirth L, Robinson B, Elisei R, et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. Asia Pac J Clin Oncol 2015;11:173.
  68. Brose MS, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial. J Clin Oncol 2014;32:A6060.
  69. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase III DECISION trial. J Clin Oncol 2013;31(Suppl. 1). doi: 10.3978/j.issn.2304-3865.2014.01.02. [DOI] [PubMed]
  70. Brose MS, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The Phase 3 decision trial. Oncol Res Treat 2014;37:130–1. doi: 10.3978/j.issn.2304-3865.2014.01.02. [DOI] [PubMed]
  71. Brose MS, Nutting C, Shong YK, Sherman SI, Smit JWA, Chung J, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the Phase III DECISION trial. Eur J Cancer 2013;49:S745.
  72. Brose MS, Nutting CM, Sherman SI, Shong YK, Smit JW, Reike G, et al. Rationale and design of decision: a double-blind, randomized, placebo-controlled Phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011;11:349. https://doi.org/10.1186/1471-2407-11-349 doi: 10.1186/1471-2407-11-349. [DOI] [PMC free article] [PubMed]
  73. Brose MS, Schlumberger M, Tahara M, Wirth LJ, Robinson B, Elisei R, et al. Effect of age and lenvatinib treatment on overall survival for patients with 131I-refractory differentiated thyroid cancer in SELECT. J Clin Oncol 2015;33:A6048.
  74. Brose MS, Teng A, Rietschel P, Habra MA. Lenvatinib and the effect of age on overall survival for patients with radioiodine-refractory differentiated thyroid cancer. Thyroid 2015;25:A290.
  75. Brose MS, Troxel AB, Harlacker K, Redlinger M, Chalian AA, Loevner LA, et al. Completion of a Phase II study of sorafenib for advanced thyroid cancer. Eur J Cancer 2009b;7:22. https://doi.org/10.1016/S1359-6349(09)72086-5 doi: 10.1016/S1359-6349(09)72086-5. [DOI]
  76. Brose MS, Troxel AB, Redlinger M, Harlacker K, Redlinger C, Chalian AA, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol 2009a;27:6002.
  77. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A Phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 2015;121:2749–56. https://doi.org/10.1002/cncr.29395 doi: 10.1002/cncr.29395. [DOI] [PMC free article] [PubMed]
  78. Chen L. Sorafenib at a low dose against radioiodine refractory metastatic papillary thyroid carcinoma in lung. Thyroid 2011;21:A58. https://doi.org/10.1089/thy.2010.0199 doi: 10.1089/thy.2010.0199. [DOI]
  79. Choi J, Abouzaid S, Li X, Rietschel P. Characteristics of patients on lenvatinib with treatment-emergent hypertension in the SELECT trial. Thyroid 2015;25:A250-a1.
  80. Cohen AB, Yarchoan M, Troxel AB, Puttaswamy K, Harlacker K, Loevner LA, et al. Phase II trial of sorafenib in advanced thyroid cancer: a disease site analysis. J Clin Oncol 2014;32(Suppl. 1).
  81. Duntas LH, Vlassopoulou V, Boutsiadis A, Mantzou E, Anapliotou M, Tsatsoulis A. Sorafenib in the treatment of radioiodine refractory thyroid cancer. A multicenter Phase II study. Eur Thyroid J 2011;0:102–3.
  82. Elisei R, Schlumberger M, Tahara M, Robinson B, Brose M, Dutcus C, et al. Subgroup analysis according to differentiated thyroid cancer histology in Phase 3 (SELECT) trial of lenvatinib. Oncol Res Treat 2015;38:25–6.
  83. Fassnacht M, Kappeler C, Healy DP, Baumer C, Meinhardt G, Elisei R, et al. Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/ or sorafenib in the Phase III DECISION study. Oncol Res Treat 2016;39:A9.
  84. Fassnacht M, Smit JW, Schlumberger M, Kappeler C, Meinhardt G, Brose MS. Management of thyroid stimulating hormone (TSH) and possible impact on outcomes for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving sorafenib or placebo on the Phase III DECISION trial. Oncol Res Treat 2016;39:8–9.
  85. Gianoukakis AG, Mathias E, Dutcus CE, Kalantari P, Yoon S. Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RRDTC). Oncol Res Treat 2016;39:307.
  86. Gianoukakis AG, Mathias EG, Dutcus C, Kalantari P, Yoon S. Response to lenvatinib treatment in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC): updated results from SELECT. J Clin Oncol 2016;34:abstract 6089.
  87. Guo M, Sherman S, Wirth L, Schlumberger M, Dutcus C, Robinson B, et al. Overall survival gain with lenvatinib vs. placebo in radioactive iodine refractory differentiated thyroid cancer (RR-DTC): an updated analysis. Eur J Cancer 2015;51:S559. https://doi.org/10.1016/S0959-8049(16)31549-0 doi: 10.1016/S0959-8049(16)31549-0. [DOI]
  88. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714–19. https://doi.org/10.1200/JCO.2008.16.3279 doi: 10.1200/JCO.2008.16.3279. [DOI] [PMC free article] [PubMed]
  89. Habra MA, Schlumberger M, Wirth L, Robinson B, Brose MS, Taylor MH, et al. Phase 3 study of (e7080) lenvatinib in differentiated cancer of the thyroid (SELECT): Results and subgroup analysis of patients from North America. Thyroid 2014;24:A100–A1.
  90. Habra MA, Song J, Rietschel P. Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: Results from a Phase 3, randomized trial. Thyroid 2015;25:A23–A4.
  91. Haddad R, Schlumberger M, Wirth L, Sherman E, Shah MH, Robinson B, et al. Incidence and timing of common adverse events in lenvatinib-treated patients with radioiodine-refractory thyroid cancer from the SELECT trial. Thyroid 2015;25:A257. doi: 10.1007/s12020-017-1233-5. [DOI] [PMC free article] [PubMed]
  92. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923–31. https://doi.org/10.1530/EJE-09-0702 doi: 10.1530/EJE-09-0702. [DOI] [PubMed]
  93. Jean GW, Mani RM, Jaffry A, Khan SA. Toxic Effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers. JAMA Oncol 2016;2:529–34. https://doi.org/10.1001/jamaoncol.2015.5927 doi: 10.1001/jamaoncol.2015.5927. [DOI] [PubMed]
  94. Kappeler C, Healy DP, Baumer C, Meinhardt G, Elisei R, Schlumberger M, et al. Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the Phase III DECISION study. J Clin Oncol 2015;33(Suppl. 1).
  95. Kappeler C, Meinhardt G, Elisei R, Brose M, Schlumberger M. Tumor growth rate analysis of progression-free survival (PFS) and overall survival (OS) for thyroid cancer patients receiving placebo or sorafenib in the Phase 3 DECISION trial. Ann Oncol 2016;27(Suppl. 6).
  96. Kawalec P. Efficacy and safety profile of lenvatinib and sorafenib in the treatment of adult patients with advanced radioactive-iodine-refractory differentiated thyroid cancer (RR-DTC). Value Health 2016;19:A708. https://doi.org/10.1016/j.jval.2016.09.2075 doi: 10.1016/j.jval.2016.09.2075. [DOI]
  97. Kawalec P, Malinowska-Lipień I, Brzostek T, Kózka M. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert Rev Anticancer Ther 2016;16:1303–9. https://doi.org/10.1080/14737140.2016.1247697 doi: 10.1080/14737140.2016.1247697. [DOI] [PubMed]
  98. Keefe SM, Troxel AB, Rhee S, Puttaswamy K, O’Dwyer PJ, Loevner LA, et al. Phase II trial of sorafenib in patients with advanced thyroid cancer. J Clin Oncol 2011;29:5562. https://doi.org/10.1200/jco.2011.29.15_suppl.5562 doi: 10.1200/jco.2011.29.15_suppl.5562. [DOI]
  99. Kiyota N, Robinson B, Shah M, Hoff AO, Taylor M, Li D, et al. Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial. Eur J Cancer 2015;51:S578. https://doi.org/10.1016/S0959-8049(16)31602-1 doi: 10.1016/S0959-8049(16)31602-1. [DOI]
  100. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, et al. Subgroup analysis of Japanese patients in a Phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci 2015;106:1714–21. https://doi.org/10.1111/cas.12826 doi: 10.1111/cas.12826. [DOI] [PMC free article] [PubMed]
  101. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675–84. https://doi.org/10.1200/JCO.2008.18.2717 doi: 10.1200/JCO.2008.18.2717. [DOI] [PMC free article] [PubMed]
  102. Kroiss M, Worden F, Shi J, Hadjieva T, Bonichon F, Gao M, et al. Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the Phase III DECISION trial. Oncol Res Treat 2014;37:269.
  103. Marotta V, Sciammarella C, Capasso M, Testori A, Pivonello C, Chiofalo MG, et al. Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine 2016;16:16. doi: 10.1007/s12020-016-1200-6. [DOI] [PubMed]
  104. McFarland DC, Misiukiewicz KJ. Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer. Onco Targets Ther 2014;7:1291–9. https://doi.org/10.2147/OTT.S49430 doi: 10.2147/OTT.S49430. [DOI] [PMC free article] [PubMed]
  105. Newbold K, Elisei R, Taylor MH, Krzyzanowska M, Shah MH, Hoff AO, et al. Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. Asia Pac J Clin Oncol 2015;11:173.
  106. Newbold K, Elisei R, Taylor MH, Krzyzanowska MK, Shah MH, Hoff AO, et al. Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy. J Clin Oncol 2015;33:A6013.
  107. Newbold K, Robinson B, Schlumberger M, Tahara M, Brose MF, Elisei R, et al. Phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT): results and subgroup analysis of patients from Europe. Eur Thyroid J 2014;3:213.
  108. Newbold K, Sherman S, Wirth LJ, Habra MA, Rietschel P, Song J, et al. The influence of time to objective response on lenvatinib clinical outcomes in the Phase 3 SELECT trial. Eur J Cancer 2015;51:S577. https://doi.org/10.1016/S0959-8049(16)31600-8 doi: 10.1016/S0959-8049(16)31600-8. [DOI]
  109. Paschke R, Bastholt L, Brose MS, Jarzab B, Schlumberger M, Siena S, et al. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodinerefractory differentiated thyroid cancer (RAI-rDTC) in the Phase III DECISION trial. Oncol Res Treat 2014;37:268–9.
  110. Paschke R, Brose MS, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the Phase 3 DECISION trial. Oncol Res Treat 2014;37:120.
  111. Paschke R, Brose MS, Nutting C, Jarzab BJ, Elisei R, Siena S, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the Phase 3 DECISION trial. Onkologie 2013;36:184.
  112. Paschke R, Brose MS, Nutting C, Shong YK, Sherman SI, Smit JWA, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the Phase III DECISION trial. Exp Clin Endocrinol Diabetes 2014;122. https://doi.org/10.1055/s-0034-1372012 doi: 10.1055/s-0034-1372012. [DOI]
  113. Paschke R, Schlumberger M, Elisei R, Pacini F, Jarzab B, Giannetta L, et al. Prognostic and predictive factors correlated with treatment outcomes for radioactive Iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the Phase III DECISION trial. Oncol Res Treat 2015;38:26. https://doi.org/10.1055/s-0035-1547604 doi: 10.1055/s-0035-1547604. [DOI]
  114. Paschke R, Schlumberger M, Nutting C, Jarzab B, Elisei R, Siena S, et al. Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the Phase III DECISION trial. Oncol Res Treat 2015;38:A186. https://doi.org/10.1055/s-0035-1547632 doi: 10.1055/s-0035-1547632. [DOI]
  115. Pena CE, Wilhelm S, Meinhardt G, Schlumberger M, Brose MS. Biomarkers of prognosis in patients with differentiated thyroid cancer: results from the DECISION trial. J Clin Oncol 2016;34.
  116. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Binder TA, Guo M, et al. Responses in specific metastases following treatment with lenvatinib (LN): results from the Phase 3 SELECT trial. Ann Oncol 2016;27. https://doi.org/10.1093/annonc/mdw376.14 doi: 10.1093/annonc/mdw376.14. [DOI]
  117. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, et al. Characterization of tumor size changes over time from the Phase 3 study of lenvatinib in thyroid cancer. J Clin Endocrinol Metab 2016;101:4103–9. https://doi.org/10.1210/jc.2015-3989 doi: 10.1210/jc.2015-3989. [DOI] [PMC free article] [PubMed]
  118. Robinson BG, Schlumberger M, Sherman SI, Tahara M, Wirth L, Brose MS, et al. Open-label extension phase outcomes of the Phase 3 SELECT trial of lenvatinib in patients with 131I-refractory differentiated thyroid cancer. Endocr Rev 2015;36.
  119. Schlumberger M, Elisei R, Pacini F, Jarzab B, Giannetta L, Bastholt L, et al. Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the Phase III decision trial. Thyroid 2014;24:A6–7.
  120. Schlumberger M, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, et al. Phase III randomized, double-blinded, placebocontrolled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes. Thyroid 2013;23:A49–50.
  121. Schlumberger M, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, et al. A randomized, double-blind, placebo controlled Phase III trial (decision) of sorafenib in locally advanced or metastatic patients with progressive radioactive iodine-refractory differentiated thyroid cancer. Eur Thyroid J 2013;2:76.
  122. Schlumberger M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the Phase III decision trial. Eur Thyroid J 2014;3:101.
  123. Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R, et al. A Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT). Oncol Res Treat 2014;37:119. https://doi.org/10.1200/jco.2014.32.18_suppl.lba6008 doi: 10.1200/jco.2014.32.18_suppl.lba6008. [DOI]
  124. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. A Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (e7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(Suppl. 1).
  125. Schneider T, Abdulrahman R, Kapiteijn E, Smit JW. Long term efficacy and tolerability of sorafenib in differentiated thyroid carcinoma: final results of a Phase II trial. Eur Thyroid J 2012;1:99. doi: 10.1530/EJE-12-0405. [DOI] [PubMed]
  126. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a Phase II trial. Eur J Endocrinol 2012;167:643–50. https://doi.org/10.1530/EJE-12-0405 doi: 10.1530/EJE-12-0405. [DOI] [PubMed]
  127. Shen CT, Qiu ZL, Luo QY. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 2014;21:253–61. https://doi.org/10.1530/ERC-13-0438 doi: 10.1530/ERC-13-0438. [DOI] [PubMed]
  128. Sherman SI, Jarzab B, Cabanillas ME, Licitra L, Pacini F, Martins RG, et al. E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC); results of a multi-center Phase II trial. Eur Thyroid J 2011;0:(0).
  129. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, et al. A Phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29:5503. https://doi.org/10.1200/jco.2011.29.15_suppl.5503 doi: 10.1200/jco.2011.29.15_suppl.5503. [DOI]
  130. Sherman SI, Schlumberger M, Tahara M, Robinson BG, Newbold K, Gianoukakis AG, et al. Relationship between thyroid-stimulating hormone levels and outcomes from the randomized, double-blind, Phase 3 study of (e7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Endocr Rev 2015;36.
  131. Sherman SI, Tahara M, Wirth L, Robinson B, Brose MF, Elisei R, et al. Analyses of a Phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). Eur Thyroid J 2014;3:74–5.
  132. Smit JW, Schlumberger M, Kappeler C, Meinhardt G, Brose MS. Management of thyroid stimulating hormone (TSH) and possible impact on outcomes for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving sorafenib or placebo on the Phase III decision trial. Thyroid 2015;25:A110.
  133. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Dutcus C, et al. Pharmacodynamic biomarkers of outcomes in the Phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2015;33(Suppl. 1).
  134. Tahara M, Wirth L, Brose MS, Newbold K, Schlumberger M, Ductus C, et al. Efficacy and safety of lenvatinib by body mass index in patients with 131I-refractory differentiated thyroid cancer from the Phase 3 SELECT study. Thyroid 2015;25:A275–6.
  135. Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results. J Clin Oncol 2016;34.
  136. Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, et al. Phase 2 study of lenvatinib in patients with differentiated, medullary and anaplastic thyroid cancer: Final analysis results. Asia Pac J Clin Oncol 2016;12:134.
  137. Terry RD, Keefe SM, Grande CM, Zifchak L, Brose MS. Timing and severity of skin-related adverse events in a Phase II trial of sorafenib (BAY43-9006) in patients with advanced thyroid cancer. J Clin Oncol 2013;31(Suppl. 1).
  138. Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19:251–8. https://doi.org/10.1634/theoncologist.2013-0362 doi: 10.1634/theoncologist.2013-0362. [DOI] [PMC free article] [PubMed]
  139. Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, et al. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015;22:877–87. https://doi.org/10.1530/ERC-15-0252 doi: 10.1530/ERC-15-0252. [DOI] [PMC free article] [PubMed]
  140. Worden FP, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, et al. Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): detailed analyses from the Phase III DECISION trial. J Clin Oncol 2014;32:A6062.
  141. Ye X, Zhu Y, Cai J. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: a meta-analysis of literature. J Cancer Res Ther 2015;11(Suppl. 2):C185–90. https://doi.org/10.4103/0973-1482.168182 doi: 10.4103/0973-1482.168182. [DOI] [PubMed]
  142. Young L, Habra M. Outcomes by site of metastasis for patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib versus placebo: results from a Phase 3, randomized trial. Asia Pac J Clin Oncol 2016;12:134.
  143. Latimer NR, Abrams KR. Adjusting Survival Time Estimates in the Presence of Treatment Switching. NICE DSU Technical Support Document 16. Sheffield: School of Health and Related Research, University of Sheffield; 2014. [PubMed]
  144. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79. https://doi.org/10.1186/1477-7525-1-79 doi: 10.1186/1477-7525-1-79. [DOI] [PMC free article] [PubMed]
  145. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9 doi: 10.1016/0168-8510(90)90421-9. [DOI] [PubMed]
  146. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70. https://doi.org/10.1186/1477-7525-5-70 doi: 10.1186/1477-7525-5-70. [DOI] [PMC free article] [PubMed]
  147. Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MÁ, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19:209–16. https://doi.org/10.1530/ERC-11-0351 doi: 10.1530/ERC-11-0351. [DOI] [PubMed]
  148. Marotta V, Ramundo V, Camera L, Del Prete M, Fonti R, Esposito R, et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol 2013;78:760–7. https://doi.org/10.1111/cen.12057 doi: 10.1111/cen.12057. [DOI] [PubMed]
  149. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588–95. https://doi.org/10.1210/jc.2009-1923 doi: 10.1210/jc.2009-1923. [DOI] [PubMed]
  150. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28:2323–30. https://doi.org/10.1200/JCO.2009.25.0068 doi: 10.1200/JCO.2009.25.0068. [DOI] [PMC free article] [PubMed]
  151. National Institute for Health and Care Excellence (NICE). Multiple Technology Appraisal. Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer after Radioactive Iodine [ID1059]. Committee Papers. London: NICE; 2017. www.nice.org.uk/guidance/ta535/documents/committee-papers (accessed 2 August 2018).
  152. MATiSSe. A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib. URL: www.clinicaltrialsregister.eu/ctr-search/trial/2006-006615-80/GB#A (accessed 7 July 2017).
  153. NEXAVAR-TC-01 (Study 17391). Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated with Sorafenib (JPMS-DTC). URL: https://clinicaltrials.gov/ct2/show/ NCT02185560 (accessed 7 July 2017).
  154. E7080-G000-211. A Phase 2 Trial of Lenvatinib (E7080) in Subjects with Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, but Have a Better Safety Profile. URL: https://clinicaltrials.gov/ct2/show/ NCT02702388 (accessed 7 July 2017).
  155. E7080-C086-308. A Trial of Lenvatinib (E7080) in Radioiodine (131I)-Refractory Differentiated Thyroid Cancer in China. URL: https://clinicaltrials.gov/ct2/show/record/ NCT02966093
  156. Brose MS, Smit JW, Lin C, Pitoia F, Fellous M, Schlumberger M, et al. Optimal timing of multikinase inhibitor initiation in radioactive iodine refractory asymptomatic patients with differentiated thyroid cancer – a global non-interventional study (RIFTOS MKI). Thyroid 2015;25:A290.
  157. NICE. Bayer HealthCare Response to AG Report to the NICE Appraisal Committee. 6 September 2017. URL: www.nice.org.uk/guidance/ta535/documents/committee-papers (accessed 7 September 2017).
  158. Huang W, Chen L, Cao V, Sung H, Yokokura M, Ting J, et al. Cost effectiveness of lenvatinib, sorafenib, and placebo in treatment of radioiodine-refractory differentiated thyroid cancer. Value Health 2016;19:A204. https://doi.org/10.1016/j.jval.2016.03.1307 doi: 10.1016/j.jval.2016.03.1307. [DOI] [PubMed]
  159. Huang W, Chen L, Ting J, Cao V, Sung H, Yokokura M, et al. The EVPI of treatment strategies for radioiodine-refractory differentiated thyroid cancer. Value Health 2016;19:A886. https://doi.org/10.1016/j.jval.2016.08.258 doi: 10.1016/j.jval.2016.08.258. [DOI]
  160. Tremblay G, Pelletier C, Copher R, Forsythe A, Majethia U. Cost-effectiveness analysis of lenvatinib as a treatment for radioactive iodine refractory differentiated thyroid cancer in the United States. Value Health 2016;19:A151. https://doi.org/10.1016/j.jval.2016.03.1595 doi: 10.1016/j.jval.2016.03.1595. [DOI]
  161. Wilson L, Huang W, Chen L, Ting J, Cao V. Cost effectiveness of lenvatinib, sorafenib and placebo in treatment of radioiodine-refractory differentiated thyroid cancer. Thyroid 2017;27:1043–52. https://doi.org/10.1089/thy.2016.0572 doi: 10.1089/thy.2016.0572. [DOI] [PubMed]
  162. Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review Final Economic Guidance Report: Lenvatinib (Lenvima) for Differentiated Thyroid Cancer. 2016. URL: www.cadth.ca/sites/default/files/pcodr/pcodr lenvatinib lenvima dtc fn egr.pdf (accessed 16 May 2017).
  163. Erdal E, Sayman H, Turkmen C, Aral F, Yildiz O, Okutur K, et al. Cost-effectiveness of sorafenib for treatment of radioactive iodine (RAI)-refractory locally advanced/metastatic differentiated thyroid cancer (DTC) in Turkey. Value Health 2015;18:A203–4. https://doi.org/10.1016/j.jval.2015.03.1178 doi: 10.1016/j.jval.2015.03.1178. [DOI]
  164. Sussman M, Munsell M, Valderrama A, Seal BS, Wen L. Estimating the economic impact of sorafenib in treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine (RAI) treatment. Value Health 2014;17:A621. https://doi.org/10.1016/j.jval.2014.08.2200 doi: 10.1016/j.jval.2014.08.2200. [DOI] [PubMed]
  165. I.H.S. Global Pricing Database. URL: http://myinsight.ihsglobalinsight.com/ (accessed 18 April 2016).
  166. American Academy of Professional Coders (AAPC). 2014 OPPS Collapses Clinic Visit E/M Levels for G0463. Salt Lake City, UT: AAPC. URL: www.aapc.com/blog/26975-2014-opps-collapses-clinic-visit-em-levels-for-g0463/ (accessed 19 April 2016).
  167. Kerr C, Fordham B, de Freitas HM, Pelletier CL, Lloyd A. Health state utility valuation in radio-iodine refractory differentiated thyroid cancer (RR-DTC). Value Health 2014;17:A646. https://doi.org/10.1016/j.jval.2014.08.2339 doi: 10.1016/j.jval.2014.08.2339. [DOI] [PubMed]
  168. Fordham BA, Kerr C, de Freitas HM, Lloyd AJ, Johnston K, Pelletier CL, et al. Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer. Patient Prefer Adherence 2015;9:1561–72. https://doi.org/10.2147/PPA.S90425 doi: 10.2147/PPA.S90425. [DOI] [PMC free article] [PubMed]
  169. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE. URL: www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 7 February 2017). [PubMed]
  170. Drummond M, Stoddart G, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. 2nd edn. Oxford: Oxford University Press; 1997.
  171. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services Research Unit, University of Kent; 2016. URL: www.pssru.ac.uk/project-pages/unit-costs/2016/index.php (accessed 28 February 2017).
  172. Bank of England. Statistical Interactive Database. London: Bank of England; 2016. URL: www.bankofengland.co.uk/boeapps/iadb/Rates.asp (accessed 26 May 2017).
  173. Georghiou T, Bardsley M. Exploring the Cost of Care at the End of Life. London: Nuffield Trust; 2014. URL: www.nuffieldtrust.org.uk/research/exploring-the-cost-of-care-at-the-end-of-life (accessed 11 July 2017).
  174. Department of Health and Social Care (DHSC). NHS Reference Costs 2015 to 2016. London: DHSC. URL: www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016 (accessed 28 February 2017).
  175. Department of Health and Social Care (DHSC). NHS Reference Costs 2014 to 2015. London: DHSC; URL: www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 (accessed 16 November 2016).
  176. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: Personal Social Services Research Unit, University of Kent; 2015. URL: www.pssru.ac.uk/project-pages/unit-costs/2015/ (accessed 11 July 2017).
  177. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database Research Data 1973–2013. Rockville, MD: National Cancer Institute. URL: www.seer.cancer.gov (accessed 20 July 2017).
  178. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury: Personal Social Services Research Unit, University of Kent; 2017.
  179. Department of Health and Social Care (DHSC). Drugs and Pharmaceutical Electronic Market Information (eMIT). London: DHSC. Updated 4 May 2016. URL: www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit (accessed 16 November 2016).
  180. Abbadessa G, Santoro A, Claudio PP. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) (June 2–6, Atlanta) 2006. Drugs Future 2006;31:617–23.
  181. Alonso-Gordoa T, Díez JJ, Durán M, Grande E. Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:22–38. https://doi.org/10.1177/1758834014551936 doi: 10.1177/1758834014551936. [DOI] [PMC free article] [PubMed]
  182. Andrews A. Sorafenib effective in metastatic differentiated thyroid cancer. Am Health Drug Benefits 2013;6.
  183. Anonymous. Sorafenib makes headway on metastatic thyroid cancer. Cancer Discov 2013;3:OF2. doi: 10.1158/2159-8290.CD-NB2013-089. [DOI] [PubMed]
  184. Anonymous. From ASCO-targeted therapies: Sorafenib shows efficacy in thyroid cancer. Nat Rev Clin Oncol 2013;11.
  185. Anonymous. Lenvatinib slows progression of thyroid cancer. Cancer Discov 2014;4:OF7. https://doi.org/10.1158/2159-8290.CD-NB2014-088 doi: 10.1158/2159-8290.CD-NB2014-088. [DOI] [PubMed]
  186. Anonymous. Lenvatinib receives approval in DTC. J Nucl Med 2015;56:12N. [PubMed]
  187. Anonymous. Lenvatinib approved for certain thyroid cancers. Cancer Discov 2015;5:338. https://doi.org/10.1158/2159-8290.CD-NB2015-029 doi: 10.1158/2159-8290.CD-NB2015-029. [DOI] [PubMed]
  188. Anonymous. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival. Prescrire Int 2016;25:37. [PubMed]
  189. Anonymous. New drugs, new indications in 2015: little progress, and threats to access to quality healthcare for all. Prescrire Int 2016;25:136–9.
  190. Antonelli A. ‘Molecular profiling and ways towards personalized medicine in advanced differentiated thyroid cancer’. Curr Genomics 2014;15:161. https://doi.org/10.2174/138920291503140609094751 doi: 10.2174/138920291503140609094751. [DOI] [PMC free article] [PubMed]
  191. Baudin E, Soria JC, Schlumberger MJ. Towards effective treatment for papillary and follicular metastatic thyroid cancer. EJC Suppl 2005;3:449–51. https://doi.org/10.1016/S1359-6349(05)80317-9 doi: 10.1016/S1359-6349(05)80317-9. [DOI]
  192. Belum VR, Marulanda K, Ensslin C, Gorcey L, Parikh T, Wu S, et al. Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 2015;26:2496–502. https://doi.org/10.1093/annonc/mdv390 doi: 10.1093/annonc/mdv390. [DOI] [PMC free article] [PubMed]
  193. Ho AL, Sherman E. Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. Clin Adv Hematol Oncol 2011;9:32–41. [PubMed]
  194. Benvenga S. Emerging therapies in sight for the fight against dedifferentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2011;96:347–50. https://doi.org/10.1210/jc.2010-2799 doi: 10.1210/jc.2010-2799. [DOI] [PubMed]
  195. Bernet V, Smallridge R. New therapeutic options for advanced forms of thyroid cancer. Expert Opin Emerg Drugs 2014;19:225–41. https://doi.org/10.1517/14728214.2014.894017 doi: 10.1517/14728214.2014.894017. [DOI] [PubMed]
  196. Bible KC. Treating advanced radioresistant differentiated thyroid cancer. Lancet Oncol 2012;13:854–5. https://doi.org/10.1016/S1470-2045(12)70342-X doi: 10.1016/S1470-2045(12)70342-X. [DOI] [PubMed]
  197. Bikas A, Vachhani S, Jensen K, Vasko V, Burman KD. Targeted therapies in thyroid cancer: an extensive review of the literature. Expert Rev Clin Pharmacol 2016;9:1299–313. https://doi.org/10.1080/17512433.2016.1204230 doi: 10.1080/17512433.2016.1204230. [DOI] [PubMed]
  198. Blair HA, Plosker GL. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. Target Oncol 2015;10:171–8. https://doi.org/10.1007/s11523-015-0363-z doi: 10.1007/s11523-015-0363-z. [DOI] [PubMed]
  199. Boudou-Rouquette P, Thomas-Schoemann A, Bellesoeur A, Goldwasser F. Sorafenib for patients with differentiated thyroid cancer. Lancet 2015;385:227–8. https://doi.org/10.1016/S0140-6736(15)60054-X doi: 10.1016/S0140-6736(15)60054-X. [DOI] [PubMed]
  200. Bradford Carter W, Tourtelot JB, Savell JG, Lilienfeld H. New treatments and shifting paradigms in differentiated thyroid cancer management. Cancer Control 2011;18:96–103. https://doi.org/10.1177/107327481101800204 doi: 10.1177/107327481101800204. [DOI] [PubMed]
  201. Brose MS. Thyroid cancer update: dramatic changes in the treatment of a rare disease. Oncology 2009;23:778, 781. [PubMed]
  202. Butler T, Maravent S, Boisselle J, Valdes J, Fellner C. A review of 2014 cancer drug approvals, with a look at 2015 and beyond. P T 2015;40:191–205. [PMC free article] [PubMed]
  203. Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 2016;42:47–55. https://doi.org/10.1016/j.ctrv.2015.11.003 doi: 10.1016/j.ctrv.2015.11.003. [DOI] [PubMed]
  204. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011;2011:985780. https://doi.org/10.4061/2011/985780 doi: 10.4061/2011/985780. [DOI] [PMC free article] [PubMed]
  205. Capdevila J, Iglesias L, Halperin I, Segura A, Vaz M, Corral J, et al. Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): a compassionate use program. J Clin Oncol 2010;28(Suppl. 1).
  206. Cappagli V, Bottici V, Molinaro E, Agate L, Viola D, Valerio L, et al. Metastatic thyroid cancer unresponsive to conventional therapy treated with sorafenib ‘off-label’: an update of our experience. Eur Thyroid J 2011;107.
  207. Clayman GL. Local treatment of differentiated thyroid carcinoma. Clin Adv Hematol Oncol 2015;13(Suppl. 4):6–9. [PubMed]
  208. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214. https://doi.org/10.1089/thy.2009.0110 doi: 10.1089/thy.2009.0110. [DOI] [PubMed]
  209. Corrado A, Ferrari SM, Politti U, Mazzi V, Miccoli M, Materazzi G, et al. Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva Endocrinol 2017;42:64–76. https://doi.org/10.23736/S0391-1977.16.02229-X doi: 10.23736/S0391-1977.16.02229-X. [DOI] [PubMed]
  210. Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther 2016;10:873–84. https://doi.org/10.2147/DDDT.S93459 doi: 10.2147/DDDT.S93459. [DOI] [PMC free article] [PubMed]
  211. Cully M. Trial watch: Multikinase-targeting therapy finds potential niche in thyroid cancer. Nat Rev Drug Discov 2015;14:229. https://doi.org/10.1038/nrd4599 doi: 10.1038/nrd4599. [DOI] [PubMed]
  212. De La Fouchardiere C, Massicotte MH, Borget I, Brassard M, Claude-Desroches M, Giraudet AL, et al. Sequential TKI treatments for iodine-refractory differentiated thyroid carcinomas. J Clin Oncol 2013;31(Suppl. 1).
  213. De Lartigue J. Lenvatinib for advanced differentiated thyroid cancer. J Community Support Oncol 2015;13:237–9. https://doi.org/10.12788/jcso.0145 doi: 10.12788/jcso.0145. [DOI]
  214. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:19–24. https://doi.org/10.1097/CCO.0b013e3282f28373 doi: 10.1097/CCO.0b013e3282f28373. [DOI] [PubMed]
  215. Dezso Z, Ino M, Minoshima Y, Tohyama O, Sugi NH, Agoulnik S, et al. Systems biology analysis to identify biomarkers for lenvatinib in the preclinical cancer cell line panels. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 2015;75.
  216. Droz J, De La Fouchardiere C, Bournaud C, Borson-Chazot F. Molecularly-targeted therapies in thyroid cancer. Ann Oncol 2010;21:viii31.
  217. Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid 2010;20:1351–8. https://doi.org/10.1089/thy.2010.0056 doi: 10.1089/thy.2010.0056. [DOI] [PubMed]
  218. Fala L. Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer. Am Health Drug Benefits 2015;8:176–9. [PMC free article] [PubMed]
  219. Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, et al. Sorafenib and thyroid cancer. BioDrugs 2013;27:615–28. https://doi.org/10.1007/s40259-013-0049-y doi: 10.1007/s40259-013-0049-y. [DOI] [PubMed]
  220. Féliz LR, Tsimberidou AM. Anti-vascular endothelial growth factor therapy in the era of personalized medicine. Cancer Chemother Pharmacol 2013;72:1–12. https://doi.org/10.1007/s00280-013-2124-y doi: 10.1007/s00280-013-2124-y. [DOI] [PubMed]
  221. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013;27:601–11. https://doi.org/10.1038/jhh.2013.30 doi: 10.1038/jhh.2013.30. [DOI] [PubMed]
  222. Gadaleta-Caldarola G, Infusino S, Divella R, Ferraro E, Mazzocca A, De Rose F, et al. Sorafenib: 10 years after the first pivotal trial. Future Oncol 2015;11:1863–80. https://doi.org/10.2217/fon.15.85 doi: 10.2217/fon.15.85. [DOI] [PubMed]
  223. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, Sonpavde G. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol 2015;94:228–37. https://doi.org/10.1016/j.critrevonc.2014.12.008 doi: 10.1016/j.critrevonc.2014.12.008. [DOI] [PubMed]
  224. Ghatalia P, Je Y, Mouallem NE, Nguyen PL, Trinh QD, Sonpavde G, Choueiri TK. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol 2015;93:257–76. https://doi.org/10.1016/j.critrevonc.2014.11.006 doi: 10.1016/j.critrevonc.2014.11.006. [DOI] [PubMed]
  225. Giuffrida D, Prestifilippo A, Scarfia A, Martino D, Marchisotta S. New treatment in advanced thyroid cancer. J Oncol 2012;2012:391629. https://doi.org/10.1155/2012/391629 doi: 10.1155/2012/391629. [DOI] [PMC free article] [PubMed]
  226. Gyawali B, Shimokata T, Honda K, Ando Y. Risk of serious adverse events (SAEs) and fatal adverse events (FAEs) with sorafenib use in patients with solid cancers: a meta-analysis of Phase 3 RCTs. Ann Oncol 2016;27. https://doi.org/10.1093/annonc/mdw390.04 doi: 10.1093/annonc/mdw390.04. [DOI] [PubMed]
  227. Haddad R. Role of multi-targeted tyrosine kinase inhibitors in RAI-refractory differentiated thyroid cancer. Clin Adv Hematol Oncol 2014;12:13–18.
  228. Hannallah J, Rose J, Guerrero MA. Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol 2013;2013:317487. https://doi.org/10.1155/2013/317487 doi: 10.1155/2013/317487. [DOI] [PMC free article] [PubMed]
  229. Haraldsdottir S, Shah MH. New era for treatment in differentiated thyroid cancer. Lancet 2014;384:286–8. https://doi.org/10.1016/S0140-6736(14)60663-2 doi: 10.1016/S0140-6736(14)60663-2. [DOI] [PubMed]
  230. Hasskarl J. Sorafenib: targeting multiple tyrosine kinases in cancer. Recent Results Cancer Res 2014;201:145–64. https://doi.org/10.1007/978-3-642-54490-3_8 doi: 10.1007/978-3-642-54490-3_8. [DOI] [PubMed]
  231. Hesselink EK, Steenvoorden D, Kapiteijn E, Corssmit E, Van Der Horst-Schrivers A, Lefrandt J, et al. Effect and toxicity of small molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: systematic review and meta-analysis. Eur Thyroid J 2014;3:130. doi: 10.1530/EJE-14-0788. [DOI] [PubMed]
  232. Hewett Y, Ghimire S, Farooqi B, Shah BK. Lenvatinib – a multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer. J Oncol Pharm Pract 2018;24:28–32. doi: 10.1177/1078155216680119. [DOI] [PubMed]
  233. Hodak SP, Carty SE. Radioiodine-resistant differentiated thyroid cancer: hope for the future. Oncology 2009;23:775–6. [PubMed]
  234. Hoftijzer HC, Kapiteijn E, Schneider T, Hovens GC, Morreau H, Gelderblom H, et al. Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clin Investig (Lond) 2011;1:241–53. https://doi.org/10.4155/cli.10.29 doi: 10.4155/cli.10.29. [DOI]
  235. Hong DS, Koetz BS, Kurzrock R, Senzer NN, Hanekom W, Naing A, et al. Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. J Clin Oncol 2010;28(Suppl. 1).
  236. Hong S, Fang W, Liang W, Yan Y, Zhou T, Qin T, et al. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. Onco Targets Ther 2014;7:1851–67. https://doi.org/10.2147/OTT.S68386 doi: 10.2147/OTT.S68386. [DOI] [PMC free article] [PubMed] [Retracted]
  237. Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies. Oncol Rep 2012;27:1303–11. https://doi.org/10.3892/or.2012.1675 doi: 10.3892/or.2012.1675. [DOI] [PubMed]
  238. Ito Y, Suzuki S, Ito K, Imai T, Okamoto T, Kitano H, et al. Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review.] Endocr J 2016;63:597–602. https://doi.org/10.1507/endocrj.EJ16-0064 doi: 10.1507/endocrj.EJ16-0064. [DOI] [PubMed]
  239. Iwasaki H, Nakayama H, Suganuma N, Yoshida T, Okamoto H, Yamanaka T, et al. Tentative treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving sorafenib or lenvatinib. Thyroid 2015;25:A262.
  240. Iwasaki H, Nakayama H, Suganuma N, Yoshida T, Yamanaka T, Hatori S, et al. Treatment outcomes of sorafenib and lenvatinib for advanced thyroid cancers and anaplastic thyroid cancers. Eur Thyroid J 2016;5:74.
  241. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943–55. https://doi.org/10.1517/14656566.2010.496453 doi: 10.1517/14656566.2010.496453. [DOI] [PubMed]
  242. Kapiteijn E, Schneider TC, Morreau H, Gelderblom H, Nortier JW, Smit JW. New treatment modalities in advanced thyroid cancer. Ann Oncol 2012;23:10–18. https://doi.org/10.1093/annonc/mdr117 doi: 10.1093/annonc/mdr117. [DOI] [PubMed]
  243. Killock D. Neuroendocrine cancer: SELECT—lenvatinib in thyroid cancer. Nat Rev Clin Oncol 2015;12:189. https://doi.org/10.1038/nrclinonc.2015.30 doi: 10.1038/nrclinonc.2015.30. [DOI] [PubMed]
  244. Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, Lefrandt JD, et al. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol 2015;172:R215–25. https://doi.org/10.1530/EJE-14-0788 doi: 10.1530/EJE-14-0788. [DOI] [PubMed]
  245. Kojic KL, Kojic SL, Wiseman SM. Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev Anticancer Ther 2012;12:345–57. https://doi.org/10.1586/era.12.8 doi: 10.1586/era.12.8. [DOI] [PubMed]
  246. Krajewska J, Jarzab B. Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. Expert Opin Orphan Drugs 2014;2:1331–40. https://doi.org/10.1517/21678707.2014.962514 doi: 10.1517/21678707.2014.962514. [DOI]
  247. Krajewska J, Handkiewicz-Junak D, Jarzab B. Sorafenib for the treatment of thyroid cancer: an updated review. Expert Opin Pharmacother 2015;16:573–83. https://doi.org/10.1517/14656566.2015.1005601 doi: 10.1517/14656566.2015.1005601. [DOI] [PubMed]
  248. Krajewska J, Kukulska A, Jarzab B. Efficacy of lenvatinib in treating thyroid cancer. Expert Opin Pharmacother 2016;17:1683–91. https://doi.org/10.1080/14656566.2016.1206078 doi: 10.1080/14656566.2016.1206078. [DOI] [PubMed]
  249. Krajewska J, Kukulska A, Jarzab B. Drug safety evaluation of lenvatinib for thyroid cancer. Expert Opin Drug Saf 2015;14:1935–43. https://doi.org/10.1517/14740338.2015.1102883 doi: 10.1517/14740338.2015.1102883. [DOI] [PubMed]
  250. Launay-Vacher V, Aapro M, De Castro G, Cohen E, Deray G, Dooley M, et al. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 2015;26:1677–84. https://doi.org/10.1093/annonc/mdv136 doi: 10.1093/annonc/mdv136. [DOI] [PubMed]
  251. Lerch C, Richter B. Pharmacotherapy options for advanced thyroid cancer: a systematic review. Drugs 2012;72:67–85. https://doi.org/10.2165/11594890-000000000-00000 doi: 10.2165/11594890-000000000-00000. [DOI] [PubMed]
  252. Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, et al. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661–67673. https://doi.org/10.18632/oncotarget.11813 doi: 10.18632/oncotarget.11813. [DOI] [PMC free article] [PubMed]
  253. Liu M, Ruan M, Chen L. Update on the molecular diagnosis and targeted therapy of thyroid cancer. Med Oncol 2014;31:973. https://doi.org/10.1007/s12032-014-0973-9 doi: 10.1007/s12032-014-0973-9. [DOI] [PubMed]
  254. Lorusso L, Newbold K. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer? Fut Oncol 2015;11:1719–27. https://doi.org/10.2217/fon.15.68 doi: 10.2217/fon.15.68. [DOI] [PubMed]
  255. Lorusso L, Pieruzzi L, Biagini A, Sabini E, Valerio L, Giani C, et al. Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther 2016;9:6467–77. https://doi.org/10.2147/OTT.S84625 doi: 10.2147/OTT.S84625. [DOI] [PMC free article] [PubMed]
  256. Ma Q, Gu LY, Ren YY, Zeng LL, Gong T, Zhong DS. Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther 2015;8:2361–74. https://doi.org/10.2147/OTT.S87298 doi: 10.2147/OTT.S87298. [DOI] [PMC free article] [PubMed]
  257. Majethia U, Frolov M, Podvyaznikov S, Rumyantsev P, Bukharova E, Tremblay G, et al. Budget impact and incremental survival benefit of using lenvatinib as a treatment for radioactive iodine refractory differentiated thyroid cancer in Russia. Value Health 2016;19:A143. https://doi.org/10.1016/j.jval.2016.03.1552 doi: 10.1016/j.jval.2016.03.1552. [DOI]
  258. Mayor S. Lenvatinib improves survival in refractory thyroid cancer. Lancet Oncol 2015;16:e110. https://doi.org/10.1016/S1470-2045(15)70066-5 doi: 10.1016/S1470-2045(15)70066-5. [DOI] [PubMed]
  259. Moreo A, Vallerio P, Ricotta R, Stucchi M, Pozzi M, Musca F, et al. Effects of cancer therapy targeting vascular endothelial growth factor receptor on central blood pressure and cardiovascular system. Am J Hypertens 2016;29:158–62. https://doi.org/10.1093/ajh/hpv077 doi: 10.1093/ajh/hpv077. [DOI] [PubMed]
  260. Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, et al. FDA approval summary: lenvatinib for progressive, radio-iodine-refractory differentiated thyroid cancer. Clin Cancer Res 2015;21:5205–8. https://doi.org/10.1158/1078-0432.CCR-15-1377 doi: 10.1158/1078-0432.CCR-15-1377. [DOI] [PubMed]
  261. Nixon IJ, Shaha AR, Tuttle MR. Targeted therapy in thyroid cancer. Curr Opin Otolaryngol Head Neck Surg 2013;21:130–4. https://doi.org/10.1097/MOO.0b013e32835aa2c2 doi: 10.1097/MOO.0b013e32835aa2c2. [DOI] [PubMed]
  262. Okamoto K, Kawada MI, Jestel A, Von Konig K, Funahashi Y, Matsushima T, et al. Distinct binding mode of lenvatinib to VEGFR2 revealed by biochemical characterization. Cancer Res 2015;75. doi: 10.1021/ml500394m. [DOI] [PMC free article] [PubMed]
  263. Pacini F, Brilli L, Marchisotta S. Targeted therapy in radioiodine refractory thyroid cancer. Q J Nucl Med Mol Imaging 2009;53:520–5. [PubMed]
  264. Pall G. ASCO annual meeting 2013: head and neck cancer. Memo 2013;6:240–3. https://doi.org/10.1007/s12254-013-0107-7 doi: 10.1007/s12254-013-0107-7. [DOI]
  265. Pall G. Post ASCO update 2014: head and neck cancer. Memo 2014;7:231–6. https://doi.org/10.1007/s12254-014-0183-3 doi: 10.1007/s12254-014-0183-3. [DOI]
  266. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol 2008;26:4701–4. https://doi.org/10.1200/JCO.2008.17.3682 doi: 10.1200/JCO.2008.17.3682. [DOI] [PubMed]
  267. Puxeddu E, Romagnoli S, Dottorini ME. Targeted therapies for advanced thyroid cancer. Curr Opin Oncol 2011;23:13–21. https://doi.org/10.1097/CCO.0b013e328340cf94 doi: 10.1097/CCO.0b013e328340cf94. [DOI] [PubMed]
  268. Qi WX, He AN, Shen Z, Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;76:348–57. https://doi.org/10.1111/bcp.12149 doi: 10.1111/bcp.12149. [DOI] [PMC free article] [PubMed]
  269. Qi WX, Tang LN, Sun YJ, He AN, Lin F, Shen Z, Yao Y. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol 2013;24:2943–52. https://doi.org/10.1093/annonc/mdt292 doi: 10.1093/annonc/mdt292. [DOI] [PubMed]
  270. Qi WX, Sun YJ, Tang LN, Shen Z, Yao Y. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2014;89:394–403. https://doi.org/10.1016/j.critrevonc.2013.10.002 doi: 10.1016/j.critrevonc.2013.10.002. [DOI] [PubMed]
  271. Ramadan S, Ugas MA, Berwick RJ, Notay M, Cho H, Jerjes W, Giannoudis PV. Spinal metastasis in thyroid cancer. Head Neck Oncol 2012;4:39. https://doi.org/10.1186/1758-3284-4-39 doi: 10.1186/1758-3284-4-39. [DOI] [PMC free article] [PubMed]
  272. Safavi A, Vijayasekaran A, Guerrero MA. New insight into the treatment of advanced differentiated thyroid cancer. J Thyroid Res 2012;2012:437569. https://doi.org/10.1155/2012/437569 doi: 10.1155/2012/437569. [DOI] [PMC free article] [PubMed]
  273. Saiyed MM, Ong PS, Chew L. Extent and outcomes of off-label drug use in oncology practice: a systematic review of literature. Ann Oncol 2015;26:ix157. https://doi.org/10.1093/annonc/mdv535.07 doi: 10.1093/annonc/mdv535.07. [DOI]
  274. Schlumberger M. Kinase inhibitors for refractory thyroid cancers. Lancet Oncol 2010;11:912–13. https://doi.org/10.1016/S1470-2045(10)70226-6 doi: 10.1016/S1470-2045(10)70226-6. [DOI] [PubMed]
  275. Schlumberger M, French TUTHYREF Network. Targeted therapy in refractory thyroid cancer. Eur J Cancer 2011;47(Suppl. 3):328–9. https://doi.org/10.1016/S0959-8049(11)70190-3 doi: 10.1016/S0959-8049(11)70190-3. [DOI] [PubMed]
  276. Schutt P, Eberhardt W. Targeted therapy for patients with thyroid cancer. Onkologie 2010;33:214.
  277. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008;37:511–24, xi. https://doi.org/10.1016/j.ecl.2008.02.005 doi: 10.1016/j.ecl.2008.02.005. [DOI] [PubMed]
  278. Sherman SI. Molecularly targeted therapies for thyroid cancers. Endocr Pract 2009;15:605–11. https://doi.org/10.4158/EP09131.RAR doi: 10.4158/EP09131.RAR. [DOI] [PubMed]
  279. Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Korte SH, et al. A Phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. J Clin Oncol 2012;30(Suppl. 1).
  280. Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Lipson BL, et al. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 2013;31(Suppl. 1).
  281. Sherman EJ, Ho AL, Fury MG, Baxi SS, Dunn L, Lee JS, et al. Combination of everolimus and sorafenib in the treatment of thyroid cancer: update on Phase II study. J Clin Oncol 2015;33.
  282. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 2012;320:130–7. https://doi.org/10.1016/j.canlet.2012.03.008 doi: 10.1016/j.canlet.2012.03.008. [DOI] [PubMed]
  283. Smit J, Brose M, Lin CC, Fellous M, Pitoia F, Sugitani I, et al. Baseline patient characteristics from RIFTOS: a global noninterventional study evaluating the use of multikinase inhibitors for treatment of asymptomatic differentiated thyroid cancer refractory to radioactive iodine (RIFTOS MKI). Eur Thyroid J 2016;5:163.
  284. Takahashi S. Molecular targeting therapy for thyroid cancer: problems in clinical practice. Ann Oncol 2014;25:v40. https://doi.org/10.1093/annonc/mdu431.3 doi: 10.1093/annonc/mdu431.3. [DOI]
  285. Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 2015;152:125–34. https://doi.org/10.1016/j.pharmthera.2015.05.009 doi: 10.1016/j.pharmthera.2015.05.009. [DOI] [PubMed]
  286. Thanigaimani S, Kichenadasse G, Mangoni AA. The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 2011;9:358–80. https://doi.org/10.2174/157016111795495503 doi: 10.2174/157016111795495503. [DOI] [PubMed]
  287. Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroid cancer. Curr Opin Oncol 2016;28:37–42. https://doi.org/10.1097/CCO.0000000000000250 doi: 10.1097/CCO.0000000000000250. [DOI] [PubMed]
  288. Tremblay G, Li X, Abouzaid S, Pelletier C. Number-needed-to-treat (NNT) analysis of therapies in radioiodine-refractory differentiated thyroid cancer (RR-DTC) using indirect comparison. Thyroid 2015;25:A266–A7.
  289. Tremblay G, Pelletier C, Forsythe A, Majethia U. Matching-adjusted indirect treatment comparison and survival extrapolation in radioiodine-refractory differentiated thyroid cancer (RAI-refractory DTC): updated analysis. Value Health 2015;18:A435. https://doi.org/10.1016/j.jval.2015.09.1048 doi: 10.1016/j.jval.2015.09.1048. [DOI]
  290. Tremblay G, Holbrook T, Milligan G, Pelletier C. Matching-adjusted indirect treatment comparison and survival extrapolation in radioiodine-refractory differentiated thyroid cancer (Rai-Refractory DTC). Value Health 2015;18:A11. https://doi.org/10.1016/j.jval.2015.03.072 doi: 10.1016/j.jval.2015.03.072. [DOI]
  291. Tremblay G, Livings C, Crowe L, Kapetanakis V, Briggs A. Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. ClinicoEcon 2016;8:323–33. https://doi.org/10.2147/CEOR.S107498 doi: 10.2147/CEOR.S107498. [DOI] [PMC free article] [PubMed]
  292. Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009;94:4423–32. https://doi.org/10.1210/jc.2009-0743 doi: 10.1210/jc.2009-0743. [DOI] [PMC free article] [PubMed]
  293. Tu SM, Bilen MA, Tannir NM. Personalised cancer care: promises and challenges of targeted therapy. J R Soc Med 2016;109:98–105. https://doi.org/10.1177/0141076816631154 doi: 10.1177/0141076816631154. [DOI] [PMC free article] [PubMed]
  294. Tuttle RM, Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 2007;5:641–6. https://doi.org/10.6004/jnccn.2007.0055 doi: 10.6004/jnccn.2007.0055. [DOI] [PubMed]
  295. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw 2014;12:1671–80. https://doi.org/10.6004/jnccn.2014.0169 doi: 10.6004/jnccn.2014.0169. [DOI] [PubMed]
  296. Vetter C. First new treatment option after 40 years: sorafenib closes therapeutic gaps in the radioiodine-refractory thyroid cancer. Oncol Res Treat 2014;37:2892–9.
  297. Wagner M, Khoury H, Bennetts L, Willet J, Lister J, Berto P, et al. Appraising the value of lenvatinib for radio-iodine refractory differentiated thyroid cancer (RR-DTC): a multi-country study applying holistic multicriteria decision analysis (MCDA). Value Health 2015;18:A477–8. https://doi.org/10.1016/j.jval.2015.09.1287 doi: 10.1016/j.jval.2015.09.1287. [DOI]
  298. Warpakowski A. Radioiodine-resistant differentiated thyroid cancer: sorafenib extends progression-free survival. Arzneimitteltherapie 2014;32:341–2.
  299. Wendling P. Sorafenib slows progression of advanced thyroid cancer. Oncol Rep 2013;30:11–12.
  300. Wirth LJ. Targeted therapy for advanced or metastatic differentiated thyroid carcinoma. Clin Adv Hematol Oncol 2015;13(Suppl. 4):9–16. [PubMed]
  301. Wong KP, Lang BH. New molecular targeted therapy and redifferentiation therapy for radioiodine-refractory advanced papillary thyroid carcinoma: literature review. J Thyroid Res 2012;2012:818204. https://doi.org/10.1155/2012/818204 doi: 10.1155/2012/818204. [DOI] [PMC free article] [PubMed]
  302. Worcester S. SELECT trial: lenvatinib effects similar regardless of site, number of metastases. Oncol Rep 2015;33:13.
  303. Yang X, Pan X, Cheng X, Cheng Y, Kuang Y. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials: Risk of sorafenib-associated death. Int J Clin Pharm 2015;37:1047–56. https://doi.org/10.1007/s11096-015-0151-y doi: 10.1007/s11096-015-0151-y. [DOI] [PubMed]
  304. Yang X, Pan X, Cheng X, Kuang Y, Cheng Y. Risk of hypertension with sorafenib use in patients with cancer: a meta-analysis from 20,494 patients. Am J Ther 2017;24:e81–e101. https://doi.org/10.1097/MJT.0000000000000331 doi: 10.1097/MJT.0000000000000331. [DOI] [PubMed]
  305. Yeung KT, Cohen EE. Lenvatinib in advanced, radioactive iodine-refractory, differentiated thyroid carcinoma. Clin Cancer Res 2015;21:5420–6. https://doi.org/10.1158/1078-0432.CCR-15-0923 doi: 10.1158/1078-0432.CCR-15-0923. [DOI] [PubMed]
  306. Yimaer W, Abudouyimu A, Tian Y, Magaoweiya S, Bagedati D, Wen H. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2016;9:1167–73. https://doi.org/10.2147/OTT.S102265 doi: 10.2147/OTT.S102265. [DOI] [PMC free article] [PubMed]
  307. Zhu C, Ma X, Hu Y, Guo L, Chen B, Shen K, Xiao Y. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. Oncotarget 2016;7:44545–57. https://doi.org/10.18632/oncotarget.10019 doi: 10.18632/oncotarget.10019. [DOI] [PMC free article] [PubMed]
  308. Zygulska AL, Krzemieniecki K, Sowa-Staszczak A. The use of sorafenib in the thyroid cancer. Euro Endocrinol 2013;9:28–31. https://doi.org/10.17925/EE.2013.09.01.28 doi: 10.17925/EE.2013.09.01.28. [DOI] [PMC free article] [PubMed]
  309. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Rockville, MD: National Cancer Institute; 2006. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (accessed 12 July 2017).
  310. Bayer HealthCare. A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer. Integrated Clinical Study Protocol BAY 43-9006/14295. Version 9.0. 2015.
  311. Eisai Ltd. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]. Eisai Response to the Assessment Report. September 2017. URL: www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers (accessed 9 October 2018).
  312. Al-Qahtani KH, Tunio MA, Al Asiri M, Fatani H, Bayoumi Y. Calvarium and dura mater as delayed sites of distant metastasis from papillary thyroid carcinoma. Int Med Case Rep J 2015;8:251–4. https://doi.org/10.2147/IMCRJ.S86183 doi: 10.2147/IMCRJ.S86183. [DOI] [PMC free article] [PubMed]
  313. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683–91. https://doi.org/10.1016/S0895-4356(97)00049-8 doi: 10.1016/S0895-4356(97)00049-8. [DOI] [PubMed]
  314. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34. https://doi.org/10.1056/NEJMoa060655 doi: 10.1056/NEJMoa060655. [DOI] [PubMed]
  315. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. https://doi.org/10.1056/NEJMoa0708857 doi: 10.1056/NEJMoa0708857. [DOI] [PubMed]
  316. Eisai Ltd. Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology. Protocol # E7080-G000-201. CSR Synopsis. URL: http://eisaiclinicaltrials.com/study/test-study-1/ (accessed 30 October 2018).

RESOURCES